Leerink downgraded ShockWave Medical (SWAV) to Market Perform from Outperform with a $335 price target after the company entered into an agreement under which Johnson & Johnson (JNJ) will acquire it for $335 per share in cash.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWAV:
- M&A News: Johnson & Johnson (NYSE:JNJ) Enters Into $13.1B Shockwave Medical Deal
- Shockwave Medical Set for Acquisition by Johnson & Johnson
- ShockWave Medical price target raised to $360 from $290 at Piper Sandler
- Piper says competitive process could materialize for ShockWave
- ShockWave Medical initiated with a Buy at CL King